fluorouracil and Cancer of Skin studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

Excerpt	Relevance	Reference
"Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)."	9.19	Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014)
"The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night."	9.16	Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. ( Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S, 2012)
"We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases."	9.12	Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007)
"Sequential methotrexate and fluorouracil chemotherapy is an effective and safe treatment for advanced mycosis fungoides and Sézary syndrome."	9.08	Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. ( Alper, JC; McDonald, CJ; Schappell, DL, 1995)
"In this study, 30 patients with metastatic breast cancer were treated with 5-Fluorouracil (5-FU) and high-dose Folinic acid, using a new sequential dosing schedule."	9.07	Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. ( Bellora, G; Bergamino, T; Ciancio, A; Ferrero, A; Katsaros, D; Sismondi, P; Zola, P, 1992)
"Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed."	9.05	The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985)
"This case report describes treatment regimens with topical calcipotriol plus fluorouracil for 2 patients with xeroderma pigmentosum."	8.31	Prevention of Skin Cancers With Topical Calcipotriol and Fluorouracil in Patients With Xeroderma Pigmentosum. ( Demehri, S; Gill, JG; Kim, J; Savory, SA, 2023)
"This study examined the effects of folate environment of oligochitosan nanoparticles on their cellular internalization profiles in human melanoma cells."	7.96	Folate-induced nanostructural changes of oligochitosan nanoparticles and their fate of cellular internalization by melanoma. ( Kumar, P; Musalli, AH; Roy, P; Talukdar, PD; Wong, TW, 2020)
"We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007."	7.91	Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019)
"5-Fluorouracil delivery profiles in the form of chitosan-folate submicron particles through skin and melanoma cells in vitro were examined using microwaves as the penetration enhancer."	7.88	Chitosan-Carboxymethyl-5-Fluorouracil-Folate Conjugate Particles: Microwave Modulated Uptake by Skin and Melanoma Cells. ( Nawaz, A; Wong, TW, 2018)
"The authors previously reported the safety and short-term efficacy of ablative fractional laser (AFXL)-assisted delivery of topical fluorouracil in the treatment of superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis)."	7.83	Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( Gan, SD; Hsu, SH; Konnikov, N; Liang, CA; Nguyen, BT, 2016)
" To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned."	7.76	The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010)
"Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer."	7.76	[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010)
"We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department."	7.73	[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006)
"Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream."	7.73	Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. ( Mings, SM; Ondo, AL; Pestak, RM; Shanler, SD, 2006)
"A case of arsenical keratosis with multiple lesions of Bowen's disease and squamous cell carcinoma is described."	7.72	Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. ( Khandpur, S; Sharma, VK, 2003)
"An 18-month-old cross-bred Fjord pony colt presenting a fibrosarcoma of the prepuce with severe infiltrative growth, was treated by topical application of 5-fluorouracil."	7.70	Successful treatment of an equine preputial fibrosarcoma using 5-fluorouracil/evaluation of the treatment using quantitative PCNA and Ki67 (MIB 1) immunostaining. (case report). ( De Kruif, A; Ducatelle, R; Roels, S; van De Vijver, B, 1998)
"A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)."	7.70	[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000)
"The case of a child with basal cell nevus syndrome whose condition was successfully managed for 10 years with a combination of topical 5-fluorouracil and tretinoin is reported."	7.68	Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. ( Lang, PG; Strange, PR, 1992)
"We have observed differential effects of the cytotoxicity of 5-fluorouracil (5-FU) on human skin melanocytes and malignant melanoma cells in vitro."	7.67	Differential effects of 5-fluorouracil on human skin melanocytes and malignant melanoma cells in vitro. ( Karasek, MA; Tsuji, T, 1986)
"Three patients with biopsy-proven lentigo maligna were treated with topical 5-fluorouracil."	7.65	Topical chemotherapy of lentigo maligna with 5-fluorouracil. ( Krementz, ET; Litwin, MS; Mansell, PW; Reed, RJ, 1975)
"In the last two years thirteen patients with keratoacanthomas were treated with 5% f-fluorouracil ointment at the Department of Dermatology II of the University of Vienna."	7.65	[The local treatment of the keratoacanthoma with 5-fluorouracil]. ( Ebner, H; Mischer, P, 1975)
"Actinic keratosis is a lesion that develops in sun-exposed areas of the skin and is considered to be a precancerous condition or an early in situ squamous cell carcinoma."	7.01	Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion. ( Bégeault, N; Delarue, A; Heppt, MV; Stockfleth, E, 2023)
"Differentiating a KA from a squamous cell carcinoma (SCC) is important for treatment implications but is often challenging."	6.61	Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature ( Doerfler, L; Hanke, CW, 2019)
"5-Fluorouracil (5-FU) is an antimetabolite drug widely used for the treatment of skin cancer."	5.72	Controlled release of 5-fluorouracil to melanoma cells using a hydrogel/micelle composites based on deoxycholic acid and carboxymethyl chitosan. ( Behbood, L; Ebrahimi, S; Jalilian, F; Janfaza, S; Limoee, M; Pourmanouchehri, Z; Vosoughi, A, 2022)
"Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules."	5.51	Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019)
" Rat skin was observed for erythema and edema and the formulation was found safe for chronic use (p˃0."	5.42	Design, Development and Characterization of Topical Microemulsions of 5-Fluorouracil for the Treatment of Non Melanoma Skin Cancer and its Precursor Lesions. ( Kumar, S; Sinha, VR, 2015)
"Using the model of B16 melanoma growing intraperitoneally in syngeneic C57BL/6 mice, we show that these GEM or 5-FU treatment regimens reduced MDSC in the peritoneal cavity of tumor-bearing mice."	5.39	Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. ( Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM, 2013)
"We describe the successful treatment of porokeratosis of Mibelli of the left calf in an 83-year-old man with topical 5 percent imiquimod and topical 5 percent 5-fluorouracil."	5.36	Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. ( LeLeux, TM; Orengo, I; Rosen, T; Venkatarajan, S; Yang, D, 2010)
"A prospective analysis was performed using data from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, a randomized, double-blinded, placebo-controlled trial of topical 5-fluorouracil for chemoprevention of KC."	5.30	Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. ( Beatson, M; Chren, MM; Siegel, JA; Weinstock, MA, 2019)
"A 58-year-old man with basal cell nevus syndrome had variously sized basal cell epitheliomas (BCEs), mostly of the superficial type, on his chest, back, and lumbar areas."	5.29	Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. ( Nishimura, M; Otake, N; Tsuji, T, 1993)
"In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C."	5.25	An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975)
"The relation between the induction of delayed hypersensitivity reactions to 5-FU following treatment with topical 5-FU and the cure rate for cutaneous neoplasms showed a trend toward correlation."	5.25	Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers. ( Ichinose, H; Krementz, ET; Litwin, MS; Mansell, PW, 1975)
"Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)."	5.19	Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014)
"The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night."	5.16	Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. ( Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S, 2012)
"We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases."	5.12	Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007)
"Sequential methotrexate and fluorouracil chemotherapy is an effective and safe treatment for advanced mycosis fungoides and Sézary syndrome."	5.08	Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. ( Alper, JC; McDonald, CJ; Schappell, DL, 1995)
"In this study, 30 patients with metastatic breast cancer were treated with 5-Fluorouracil (5-FU) and high-dose Folinic acid, using a new sequential dosing schedule."	5.07	Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. ( Bellora, G; Bergamino, T; Ciancio, A; Ferrero, A; Katsaros, D; Sismondi, P; Zola, P, 1992)
"Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed."	5.05	The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985)
"The mainstream treatments for non-melanoma skin cancer (NMSC) include photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod (IM), radiotherapy (RT), 5-fluorouracil (FU), and vehicle (VE)."	4.95	A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment. ( Lv, R; Sun, Q, 2017)
" Keratoacanthomas had high cure rates with intralesional agents: 98% for 5FU, 91% for methotrexate, 100% for bleomycin, 100% for IFN alpha (α)-2, 83% for IFN α-2a, and 100% for IFN α-2b."	4.89	Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. ( Chitwood, K; Cohen, G; Etzkorn, J, 2013)
"This case report describes treatment regimens with topical calcipotriol plus fluorouracil for 2 patients with xeroderma pigmentosum."	4.31	Prevention of Skin Cancers With Topical Calcipotriol and Fluorouracil in Patients With Xeroderma Pigmentosum. ( Demehri, S; Gill, JG; Kim, J; Savory, SA, 2023)
"Studies comparing 5-fluorouracil (5-FU), imiquimod, and photodynamic therapy with aminolevulinic acid (PDT-ALA) have evaluated the efficacy of destroying actinic keratosis (AK)."	4.12	A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. ( Cheng, B; Etzkorn, JR; Giordano, CN; Higgins, HW; Miller, CJ; Shin, TM; Sobanko, JF; Veerabagu, S, 2022)
"This study examined the effects of folate environment of oligochitosan nanoparticles on their cellular internalization profiles in human melanoma cells."	3.96	Folate-induced nanostructural changes of oligochitosan nanoparticles and their fate of cellular internalization by melanoma. ( Kumar, P; Musalli, AH; Roy, P; Talukdar, PD; Wong, TW, 2020)
"Topical 5-fluorouracil (5-FU) is a valuable treatment of actinic keratosis (AK), but its use is limited by bothersome side effects."	3.96	Group clinic for chemoprevention of squamous cell carcinoma: a pilot study. ( Beatson, M; Landow, SM; Leader, N; Shaw, FM; Weinstock, MA, 2020)
"We identified 5700 subjects who filled prescriptions for 5-fluorouracil or imiquimod for treatment of actinic keratosis in 2007."	3.91	Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. ( Asgari, MM; Chren, MM; Friedman, GD; Neugebauer, R; Sokil, M; Su, KA; Zhu, Z, 2019)
" Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted."	3.91	[A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome]. ( Hirai, A; Ichiki, Y; Imanishi, N; Ishida, T; Kusanagi, K; Shinohara, S; Takeda, Y; Tanaka, F; Tashima, Y; Yoshimatsu, K, 2019)
"5-Fluorouracil delivery profiles in the form of chitosan-folate submicron particles through skin and melanoma cells in vitro were examined using microwaves as the penetration enhancer."	3.88	Chitosan-Carboxymethyl-5-Fluorouracil-Folate Conjugate Particles: Microwave Modulated Uptake by Skin and Melanoma Cells. ( Nawaz, A; Wong, TW, 2018)
"A 60-year-old woman with cutaneous metastases from heavily pretreated HER2-positive breast cancer received CMFVP (oral cyclophosphamide 100 mg daily; oral prednisone 12."	3.83	Response of extensive breast cancer skin metastases to rechallenge with trastuzumab together with low-dose chemotherapy and insulin. ( Calvani, N; Cinieri, S; Fedele, P; Goldhirsch, A; Orlando, L; Schiavone, P, 2016)
"The authors previously reported the safety and short-term efficacy of ablative fractional laser (AFXL)-assisted delivery of topical fluorouracil in the treatment of superficial basal cell carcinoma (sBCC) and squamous cell carcinoma in situ (SCCis)."	3.83	Ablative Fractional Laser-Assisted Topical Fluorouracil for the Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ: A Follow-Up Study. ( Gan, SD; Hsu, SH; Konnikov, N; Liang, CA; Nguyen, BT, 2016)
" To investigate the molecular basis for the effect of TP on the metabolic process and the anticancer effect of 5-fluorouracil (5-FU), human gastric carcinoma AZ521 cells and epidermoid carcinoma KB cells were transfected with TP cDNA, and AZ521/TP and KB/TP were cloned."	3.76	The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. ( Akiyama, S; Che, XF; Furukawa, T; Ikeda, R; Kanekura, T; Kanzaki, T; Mataki, H; Matsushita, S; Minami, K; Miyadera, K; Nishizawa, Y; Tabata, S; Tajitsu, Y; Takeda, Y; Ushiyama, M; Yamada, K; Yamamoto, M, 2010)
"Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer."	3.76	[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010)
"High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer."	3.74	[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007)
"to evaluate the feasibility, tolerance/toxicity and therapeutic efficacy of 5-fluorouracil (5-FU) by topical application and systemic use, in facial carcinoma associated with XP."	3.73	[Topical and systemic chemotherapy with 5-fluouracil in facial carcinoma secondary to xeroderma pigmentosum]. ( Boussen, H; Boussen, I; Ferjaoui, M; Gritli, S; Khader, A; Ladgham, A; Nouira, R; Oueslati, Z, 2005)
"We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department."	3.73	[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006)
"Topical therapeutic options for cutaneous squamous cell carcinoma in situ include 5-fluorouracil cream and imiquimod cream."	3.73	Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. ( Mings, SM; Ondo, AL; Pestak, RM; Shanler, SD, 2006)
"A case of arsenical keratosis with multiple lesions of Bowen's disease and squamous cell carcinoma is described."	3.72	Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. ( Khandpur, S; Sharma, VK, 2003)
" We report the 1st case of capecitabine-induced toxic encephalopathy with epilepsy-like symptoms and diffuse white matter alterations on magnetic resonance imaging."	3.72	Toxic encephalopathy induced by capecitabine. ( Herrmann, R; Niemann, B; Pless, M; Rochlitz, C, 2004)
"An 18-month-old cross-bred Fjord pony colt presenting a fibrosarcoma of the prepuce with severe infiltrative growth, was treated by topical application of 5-fluorouracil."	3.70	Successful treatment of an equine preputial fibrosarcoma using 5-fluorouracil/evaluation of the treatment using quantitative PCNA and Ki67 (MIB 1) immunostaining. (case report). ( De Kruif, A; Ducatelle, R; Roels, S; van De Vijver, B, 1998)
"An 83-year-old Caucasian man with cutaneous T-cell lymphoma developed an aggressive squamous cell carcinoma of the left forearm, which recurred and metastasized after Mohs micrographic surgery and systemic chemotherapy with cis-platin and 5-fluorouracil."	3.70	Invasive squamous cell carcinoma with sporotrichoid metastasis in a patient with cutaneous T cell lymphoma treated with chronic extracorporeal photopheresis. ( Beer, R; Elizeri, Y; Gmyrek, R; Grossman, ME; Oster, MW; Schneiderman, P; Silvers, DN, 1999)
"A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)."	3.70	[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000)
"The case of a child with basal cell nevus syndrome whose condition was successfully managed for 10 years with a combination of topical 5-fluorouracil and tretinoin is reported."	3.68	Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. ( Lang, PG; Strange, PR, 1992)
"We have observed differential effects of the cytotoxicity of 5-fluorouracil (5-FU) on human skin melanocytes and malignant melanoma cells in vitro."	3.67	Differential effects of 5-fluorouracil on human skin melanocytes and malignant melanoma cells in vitro. ( Karasek, MA; Tsuji, T, 1986)
"Seven patients with advanced cutaneous T-cell lymphomas were treated with a combination chemotherapy regimen of vincristine, doxorubicin (Adriamycin), bleomycin, methotrexate, leucovorin factor, 5-FU, and hydrocortisone."	3.66	Combination chemotherapy for advanced cutaneous T-cell lymphomas. ( Edelson, RL; Lo Gerfo, P; Oster, MW; Raafat, J, 1980)
"Successful management of keratoacanthomas and basal-cell epitheliomas by intralesional injections of 5-fluorouracil is reported."	3.66	Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). ( Kurtis, B; Rosen, T, 1980)
"15 patients with superficial basaliomas or premalignant epithelial neoplastic disorders (actinic keratosis, leukoplakia, Bowen's disease) were treated locally over three weeks with retinoic acid (RA) alone or in combination with 5-fluorouracil (5-FU)."	3.66	[Vitamin A acid for the topical management of epithelial neoplasms. Combination with 5-fluorouracil]. ( Kurka, M; Orfanos, CE; Pullmann, H, 1978)
"Three patients with biopsy-proven lentigo maligna were treated with topical 5-fluorouracil."	3.65	Topical chemotherapy of lentigo maligna with 5-fluorouracil. ( Krementz, ET; Litwin, MS; Mansell, PW; Reed, RJ, 1975)
"In the last two years thirteen patients with keratoacanthomas were treated with 5% f-fluorouracil ointment at the Department of Dermatology II of the University of Vienna."	3.65	[The local treatment of the keratoacanthoma with 5-fluorouracil]. ( Ebner, H; Mischer, P, 1975)
"Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle."	3.65	Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976)
"Non-melanoma skin cancer is one of the most common malignancies reported around the globe."	3.01	Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer. ( Ahmad, FJ; Hasan, N; Imran, M; Jaimini, A; Jain, GK; Kesharwani, P; Sheikh, A; Tiwari, N, 2023)
"Actinic keratosis is a lesion that develops in sun-exposed areas of the skin and is considered to be a precancerous condition or an early in situ squamous cell carcinoma."	3.01	Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion. ( Bégeault, N; Delarue, A; Heppt, MV; Stockfleth, E, 2023)
"Skindex and Skin Cancer Index (SCI) are validated instruments to measure quality of life (QoL) of patients with KC and those who have had surgical treatment of KCs."	2.84	Validation and comparison of quality-of-life measures for topical 5-fluorouracil treatment: results from a randomized controlled trial. ( Chren, MM; Lew, R; Pomerantz, H; Weinstock, MA, 2017)
" Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis."	2.84	Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. ( Cornelius, LA; Cunningham, TJ; Demehri, S; Eliane, JP; Kopan, R; Manivasagam, S; Mirzaalian, H; Saavedra, AP; Schaffer, A; Tabacchi, M; Tuchayi, SM; Turkoz, A; Wallendorf, M, 2017)
"Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself."	2.76	Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. ( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011)
"Imiquimod treatment of AK resulted in superior sustained clearance and cosmetic outcomes compared with cryosurgery and 5-FU."	2.73	A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. ( Krawtchenko, N; Mann, I; Roewert-Huber, J; Sterry, W; Stockfleth, E; Ulrich, M, 2007)
"Fluorouracil was applied for 4 weeks."	2.72	Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. ( Bedane, C; Horn, M; Ibbotson, S; Khemis, A; Leman, J; Morton, C; Tack, B; Tjioe, M; Wolf, P, 2006)
"Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =."	2.72	Facial resurfacing for nonmelanoma skin cancer prophylaxis. ( Cooper, ZA; Hantash, BM; Koch, RJ; Rehmus, WE; Stewart, DB; Swetter, SM, 2006)
"An alternative approach to anal Bowen's disease was investigated."	2.71	Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. ( Arnold, LK; Foote, JE; Graham, BD; Jetmore, AB, 2005)
"Chemotherapy for squamous cell carcinoma with unknown primary (SCUP) has not been prospectively studied."	2.68	Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. ( Allred, C; Anand, V; Khansur, T; Little, D, 1995)
"Topical treatment of skin cancer may therefore be more appropriate in certain instances."	2.66	Topical treatments for skin cancer. ( Boyle, GM; Cullen, JK; Parsons, PG; Simmons, JL, 2020)
"AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC."	2.66	Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020)
"Skin cancer is a high burden disease with a high impact on global health."	2.66	Nanotechnology approaches in the current therapy of skin cancer. ( Bentley, MVLB; Borgheti-Cardoso, LN; Caron, AL; Kravicz, M; Praça, FG; Silvestrini, AVP; Viegas, JSR, 2020)
"We summarize the types of skin cancers and practices in current clinical management."	2.66	Nanoparticles for topical drug delivery: Potential for skin cancer treatment. ( Krishnan, V; Mitragotri, S, 2020)
"Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer."	2.61	Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma. ( Bhatta, AK; Keyal, U; Wang, XL; Zhang, G, 2019)
"Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers."	2.61	Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019)
"Differentiating a KA from a squamous cell carcinoma (SCC) is important for treatment implications but is often challenging."	2.61	Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature ( Doerfler, L; Hanke, CW, 2019)
"5-fluorouracil has proven to be an effective therapy in the treatment of a variety of dermatologic conditions."	2.58	Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. ( Alkousakis, T; Cameron, MC; Fathi, R; Prince, GT, 2018)
"Nonmelanoma skin cancer (NMSC) is the most common cancer in patients and includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)."	2.53	Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. ( Cherpelis, B; Rudnick, EW; Thareja, S, 2016)
"The treatment paradigm for nonmelanoma skin cancer remains surgical."	2.53	Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review. ( Metterle, L; Nelson, C; Patel, N, 2016)
"The incidence of cutaneous squamous cell carcinomas (SCCs) in immunosuppressed solid organ transplant recipients (SOTRs) is 65- to 250-fold greater than in the general population."	2.53	Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. ( Cheng, J; Colegio, OR; Kim, C, 2016)
"In general, people with Bowen's disease have an excellent prognosis because the disease is typically slow-growing and responds favourably to treatment."	2.49	Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013)
"Nonmelanoma skin cancer, which encompasses basal cell and squamous cell carcinoma, is the most common cancer in the United States."	2.48	Diagnosis and treatment of Basal cell and squamous cell carcinoma. ( Firnhaber, JM, 2012)
"With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed."	2.47	Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011)
"The management of low risk squamous cell carcinoma with topical therapies, photodynamic therapy, systemic retinoids, and capecitabine is reviewed."	2.47	Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. ( Brown, M; O'Reilly Zwald, F, 2011)
"Skin cancer is one of the most commonly occurring cancer types, with substantial social, physical, and financial burdens on both individuals and societies."	2.45	Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer. ( Grealy, R; Griffiths, LR, 2009)
"Fluorouracil has been the traditional topical treatment for actinic keratoses, although imiquimod 5% cream and diclofenac 3% gel are effective alternative therapies."	2.44	Treatment options for actinic keratoses. ( Bedwell, SA; Downs, MR; McIntyre, WJ, 2007)
"An updated review of management of nevoid basal cell carcinoma syndrome (NBCCS) is presented."	2.44	Nevoid basal cell carcinoma syndrome (Gorlin syndrome): updated review of minimally invasive treatments. ( Mitropoulos, P; Norman, R, 2008)
"Actinic keratosis is a precancerous lesion that is commonly seen in the elderly patient and requires treatment."	2.43	[Actinic keratosis]. ( Dissemond, J; Grabbe, S, 2006)
"Actinic keratosis is currently believed to be an early stage in the evolution of squamous cell carcinoma."	2.42	Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003)
"The lesions of Bowen's disease are slow-growing, erythematous scaly skin plaques that cause few, if any, symptoms."	2.42	Management of Bowen's disease of the skin. ( , 2004)
"The ability to manage non-melanoma skin cancers and pre-malignant lesions with topical pharmacologic agents is highly compelling."	2.42	Topical treatment strategies for non-melanoma skin cancer and precursor lesions. ( Fein, H; McGillis, ST, 2004)
"Actinic keratoses are superficial squamous cell carcinomas."	2.42	Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). ( Fenske, NA; Lober, BA, 2004)
"An integrated program of skin cancer awareness, sun protection, and prophylactic approaches is critical."	2.41	Nonmelanoma skin cancer. ( Ho, DQ; Nguyen, TH, 2002)
"Advanced extramammary Paget's disease is also adenocarcinoma of the skin."	2.40	[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature]. ( Yamazaki, N, 1997)
"Actinic cheilitis is a common premalignant condition, significant for symptoms and potential development into invasive squamous cell carcinoma."	2.40	Actinic cheilitis. A treatment review. ( Curlin, MU; Dufresne, RG, 1997)
"Amelanotic lentigo maligna melanoma (ALMM) is an infrequent presentation of lentigo maligna melanoma, less than thirty cases having been reported to date."	2.40	Amelanotic lentigo maligna melanoma: report of a case and review of the literature. ( de Moragas, JM; Puig, L; Rocamora, V; Romaní, J, 1999)
"An early diagnosis and treatment of Bowen's disease is important for preventing its progression to invasive epidermoid carcinoma and later dissemination."	2.39	[Bowen's disease. A report of 9 cases]. ( Borbujo Martínez, J; de Miguel Sánchez, C; Gázquez Abad, I; Olmos Carrasco, O; Rodríguez García, MD; Sáez-Berlana, A, 1994)
"Melanoma is a disease that need not be deadly."	2.38	The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993)
"Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma."	2.38	Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. ( Lentz, SR; Marion, JM; Orlowski, EP; Raish, RJ, 1990)
"The potential impact on cancer mortality from these treatment results is obvious."	2.36	Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. ( DeVita, VT; Weiss, RB, 1979)
"Non-melanoma skin cancer is one of the most common malignancies reported with high number of morbidities, demanding an advanced treatment option with superior chemotherapeutic effects."	1.91	Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer. ( Haider, K; Hasan, N; Imran, M; Jain, D; Jalees Ahmad, F; Kesharwani, P; Kumar Jain, G; Moshahid Alam Rizvi, M; Nadeem, M; Sheikh, A, 2023)
"Dermatological interventions and skin cancer-related medical prescriptions were documented."	1.91	Patterns and cost of care according to keratinocyte cancer risk stratification in a volunteer population screening clinic: Real-world data from the TRoPICS study. ( Brown, S; Fry, K; Gordon, LG; Janda, M; Khosrotehrani, K; Lee, RC; Liyanage, U; Neale, RE; Olsen, CM; Soyer, HP; Spelman, L; von Schuckmann, L; Whiteman, DC, 2023)
"Non-melanoma skin cancer (NMSC), which includes both Bowen's disease (BD) and superficial basal cell carcinoma (sBCC), is the most commonly diagnosed cancer in Canada."	1.91	Cryosurgery and 5-Fluorouracil Combination Therapy for Treatment of Bowen's Disease and Superficial Basal Cell Carcinoma. ( Nazarali, S; Sajic, D, 2023)
"AFL-assisted cisplatin + 5-FU in double sessions represents an acceptable and safe treatment strategy for low-risk sBCC, while clearance rates following single treatment or for nBCC seem inferior."	1.72	Efficacy and safety of laser-assisted combination chemotherapy: A follow-up study of treatment with 5-fluorouracil and cisplatin for basal cell carcinoma. ( Fredman, G; Haedersdal, M; Hendel, K; Togsverd-Bo, K; Wenande, E, 2022)
"5-Fluorouracil (5-FU) is an antimetabolite drug widely used for the treatment of skin cancer."	1.72	Controlled release of 5-fluorouracil to melanoma cells using a hydrogel/micelle composites based on deoxycholic acid and carboxymethyl chitosan. ( Behbood, L; Ebrahimi, S; Jalilian, F; Janfaza, S; Limoee, M; Pourmanouchehri, Z; Vosoughi, A, 2022)
"Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years."	1.72	In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC. ( Gilaberte, Y; González, S; Gutiérrez-Pérez, M; Juarranz, Á; Nicolás-Morala, J; Portillo-Esnaola, M; Terrén, S, 2022)
" It provides a promising long-term relief with a tolerable side-effect profile."	1.72	Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas. ( Gupta, P; Kaur, M; Mehta Grewal, A; Sharma, M; Singh, H; Singh, M; Zadeng, Z, 2022)
"Local skin cancer recurrence occurs in ∼12% of the patients post-surgery due to persistent growth of residual cancer cells."	1.62	Synthesis and characterization of a novel pH-responsive drug-releasing nanocomposite hydrogel for skin cancer therapy and wound healing. ( Gonsalves, A; Le, D; Menon, JU; Nguyen, KT; Tambe, P; Thakore, D; Wadajkar, AS; Yang, J, 2021)
"Mitomycin C was more effective in inducing the apoptosis of basal cell carcinoma than 5-fluorouracil and their combination."	1.62	Optimizing the effective doses of mitomycin C, 5-fluorouracil, and their combination on cultivated basal cell carcinoma. ( Aletaha, M; Balagholi, S; Dabbaghi, R; Kanavi, MR; Karami, S; Nakhaie, PA, 2021)
"Little guidance on management of basal cell nevus syndrome in children exists."	1.56	A pediatric approach to management of skin growths in basal cell nevus syndrome. ( Bartenstein, DW; Fisher, J; Hawryluk, EB; Kroshinsky, D; Lilly, E; Moustafa, D; Su, KA, 2020)
"Introduction: Standard of care for squamous cell carcinoma (SCC) is usually surgical, with either excision or Mohs micrographic surgery."	1.56	Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma ( Fayne, R; Nanda, S; Nichols, A; Shen, J, 2020)
"Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor."	1.56	Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report. ( Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G, 2020)
"When treating invasive basal cell carcinoma (BCC) with Mohs micrographic surgery (MMS), including infiltrative and nodular subtypes, the goal is complete surgical removal of the tumor."	1.56	Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery. ( Housewright, C; Pederson, H; Staples, CJ, 2020)
"Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules."	1.51	Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019)
"Actinic keratoses (AKs) and squamous cell carcinoma in situ (SCCIS) are precursor lesions for cutaneous squamous cell carcinoma (cSCC), the second most common form of cancer."	1.51	Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma. ( Beer, J; D'Armas, S; Daifallah, AEM; Dentchev, T; Farag, AM; Hahn, J; Lee, V; Marshall, C; Sabry, HH; Seykora, F; Seykora, JT; Shankar, S; Yang, X, 2019)
" A novel semisolid dosage form enriched by NLC which is promising for topical treatment of skin cancers was developed."	1.51	QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment. ( Aksu, B; Amasya, G; Badilli, U; Onay-Besikci, A; Tarimci, N, 2019)
"5-fluorouracil (5-FU) is a cytostatic drug associated with antimetabolite effects and already approved as monotherapy for superficial BCCs treatment."	1.51	Basal cell carcinomas treated with 0.5% 5-fluorouracil and 10% salicylic acid topical solution. ( Bianchi, L; Campione, E; Diluvio, L; Lanna, C; Lozzi, F; Palumbo, V, 2019)
"The incidence rate of skin cancer has continuously increased over the past decades."	1.48	A novel tubulin inhibitor STK899704 induces tumor regression in DMBA/TPA-induced skin carcinogenesis model. ( Ahn, JS; Cha-Molstad, H; Choi, TW; Han, HJ; Hong, JT; Hwang, J; Kim, BY; Kim, HJ; Kwon, YT; Lee, HG; Lee, KH; Lee, Y; Mun, J; Soung, NK, 2018)
"Superficial basal cell carcinoma is a type of keratinocyte carcinoma that has increasing incidence and substantial morbidity."	1.48	Comparing Topical Treatments for Basal Cell Carcinoma. ( Shaw, FM; Weinstock, MA, 2018)
"Fluorouracil (5-FU) is an antimetabolite drug used in the treatment of various malignancies, such as colon and skin cancers."	1.48	Fluorouracil-Loaded Gold Nanoparticles for the Treatment of Skin Cancer: Development, in Vitro Characterization, and in Vivo Evaluation in a Mouse Skin Cancer Xenograft Model. ( Attia, MA; Safwat, MA; Sayed, D; Soliman, GM, 2018)
"Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer in the United States."	1.48	Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma ( Mackey, M; Mackey, VT; Shahsavari, A, 2018)
"Nonmelanoma skin cancer is the most common cancer in humans, comprising mainly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)."	1.46	Anticancer drugs and the regulation of Hedgehog genes GLI1 and PTCH1, a comparative study in nonmelanoma skin cancer cell lines. ( Bojesen, S; Gehl, J; Haedersdal, M; Olesen, UH, 2017)
"The wool hydrolysates decreased squamous cell carcinoma cells viability by up to 67% comparing to untreated cells."	1.46	The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. ( Borkowska, JK; Czuwara, J; Damps, T; Konop, M; Kowalkowski, T; Laskowska, AK; Misicka, A; Prokopowicz, M; Puszko, AK; Różycki, K; Rudnicka, L; Sosnowski, P, 2017)
"Topical chemotherapy of skin cancers is a promising strategy for reduction of side effects and for improvement of patient compliance."	1.46	Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells. ( Eloy, JO; Lee, RJ; Lopez, RF; Petrilli, R, 2017)
"Cotreatment with celecoxib and 5-FU partially blocked AKT phosphorylation, although no significant changes in total AKT protein levels were detected."	1.46	Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. ( Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW, 2017)
"Although squamous cell carcinoma (SCC) is the second most common nonmelanoma skin cancer, clinicians have difficulty diagnosing SCC of the toe because its clinical features can mimic other less serious diseases."	1.43	A Digital Squamous Cell Carcinoma Mimicking a Diabetic Foot Ulcer, With Early Inguinal Metastasis and Cancer-Related Lymphedema. ( Kim, HW; Kim, JE; Ko, JY; Kwon, HI; Park, HC; Ro, YS, 2016)
"Toxicity was acceptable, with grade 3 renal failure (n=1) and grade 3 or 4 myelotoxicity (n=2)."	1.43	Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. ( Dietrich, PY; Espeli, V; Hottinger, AF; Modarressi, A; Ruegg, E, 2016)
"5-fluorouracil (5-Fu) is an antineoplastic drug, topically used for the treatment of actinic keratosis and nonmelanoma skin cancer."	1.42	Novel carbopol-based transfersomal gel of 5-fluorouracil for skin cancer treatment: in vitro characterization and in vivo study. ( Ali, A; Aqil, M; Chauhan, M; Khan, MA; Pandit, J; Sultana, S; Sultana, Y, 2015)
"Skin cancer has turned into global epidemic leading to higher incidences among cancer stricken population."	1.42	Nanovesicular carrier-based formulation for skin cancer targeting: evaluation of cytotoxicity, intracellular uptake, and preclinical anticancer activity. ( Ganesh, N; Jain, SK; Mahajan, M; Pathak, CM; Puri, R; Yadav, S, 2015)
"The incidence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK), squamous cell carcinoma (SCC), Bowen's Disease (BD) and basal cell carcinoma (BCC), is increasing."	1.42	Field cancerization: from molecular basis to selective field-directed management of actinic keratosis. ( Philipp-Dormston, WG, 2015)
" Rat skin was observed for erythema and edema and the formulation was found safe for chronic use (p˃0."	1.42	Design, Development and Characterization of Topical Microemulsions of 5-Fluorouracil for the Treatment of Non Melanoma Skin Cancer and its Precursor Lesions. ( Kumar, S; Sinha, VR, 2015)
"Non-melanoma skin cancer (NMSC) is the most common form of skin cancer."	1.40	Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2014)
"Case 1 was a 61-year-old man with squamous cell carcinoma of the urethra that directly invaded into the perineal skin."	1.40	Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. ( Arai, Y; Itoh, J; Kaiho, Y; Kimura, S; Mitsuzuka, K; Saito, H; Tanaka, T; Yamada, S; Yamamuro, T; Yamashita, S, 2014)
"Using the model of B16 melanoma growing intraperitoneally in syngeneic C57BL/6 mice, we show that these GEM or 5-FU treatment regimens reduced MDSC in the peritoneal cavity of tumor-bearing mice."	1.39	Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. ( Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM, 2013)
"Apigenin has an antioxidant capacity as well as the ability to inhibit lipid peroxidation."	1.38	Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. ( Chan, LP; Chen, PR; Chiang, FY; Chou, TH; Ding, HY; Kuo, PL; Liang, CH, 2012)
"In early-stage breast cancer, radiotherapy delivered after conservative surgery leads to a reduction in the risk of local recurrences by approximately two thirds."	1.38	[A case of cutaneous mammary re-irradiation]. ( Bollet, MA; Fourchotte, V; Jacob, J; Kirova, YM; Pierga, JY, 2012)
"Tumour histology was squamous cell carcinoma in 74% of the cases."	1.37	[Radiotherapy for cutaneous cancers with xeroderma pigmentosum]. ( Abdelmoula, M; Bahri, M; Ben Salah, H; Daoud, J; Frikha, M; Turki, H, 2011)
" Skin permeation and retention showed better permeability and retention than the nonvesiculized dosage form."	1.37	Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. ( Ali, A; Alvi, IA; Kaushik, D; Madan, J; Pandey, RS; Sardana, S, 2011)
" The most common side effect of this medication is localized irritant dermatitis."	1.37	Metallic taste as a side effect of topical fluorouracil use. ( Han, SY; Youker, S, 2011)
"Non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, also represent sun-related conditions that require early and aggressive treatment."	1.36	Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. ( Goldsmith, A; Han, A; Marmur, ES; Penrose, C, 2010)
"We describe the successful treatment of porokeratosis of Mibelli of the left calf in an 83-year-old man with topical 5 percent imiquimod and topical 5 percent 5-fluorouracil."	1.36	Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. ( LeLeux, TM; Orengo, I; Rosen, T; Venkatarajan, S; Yang, D, 2010)
"Managing patients with diffuse squamous cell carcinoma (SCC) and actinic damage on their extremities is challenging because SCCs may be ill-defined, confluent, and only amenable to radical surgery."	1.35	Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. ( Berk, DR; Mann, M; Petersen, J, 2008)
"A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy."	1.35	Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. ( Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A, 2008)
"Aggressive skin cancers are common in this population."	1.35	Skin cancer and the solid organ transplant recipient. ( Liégeois, NJ; Patel, MJ, 2008)
"The most common metastatic sites from gastric cancer are the liver, intra-abdominal lymph nodes, ovary and peritoneal cavity."	1.34	Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer. ( Chang, HM; Jung, JY; Kang, YK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Ryu, MH; Song, JH; Song, JS; Yook, JH, 2007)
"A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion."	1.34	[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases]. ( Akagawa, T; Fujioka, S; Hara, T; Hiramatsu, K; Hirata, A; Ito, T; Kato, K; Kutsuna, Y; Machiki, Y; Matsuba, H; Miyata, T, 2007)
" Taken together, the results suggest that a poloxamer gel system with 5-FU/P188/PG is an effective rectal dosage form for the treatment of both rectal and non-rectal cancers."	1.33	Poloxamer 188 and propylene glycol-based rectal suppository enhances anticancer effect of 5-fluorouracil in mice. ( Choi, HG; Jeong, TC; Jin, CH; Kim, JA; Lee, YS; Oh, YK; Paek, SH; Park, BC; Xuan, JJ, 2006)
"The murine AT-84 orthotopic model of oral cancer was assessed to find how similar it is to human oral cancer."	1.32	Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. ( Hutchison, R; Kellman, RM; Lou, E; Shillitoe, EJ, 2003)
"5-Fluorouracil (5-FU) has been used topically and intralesionally to treat lesions related to squamous cell carcinoma (SCC) such as actinic keratosis, Bowen's disease, and keratoacanthoma."	1.32	Treatment of squamous cell carcinoma with intralesional 5-Fluorouracil. ( Hooper, D; Kendrick, C; Morse, LG; Parry, E; Ward, H, 2003)
"Carcinosarcoma is a biphasic tumor composed of malignant epithelial and mesenchymal elements."	1.32	Primary sweat gland carcinosarcoma of the scrotal skin. ( Huang, WJ; Lin, TP; Murphy, GF; Pan, CC, 2004)
"5-fluorouracil (5-FU) treatment is also widely utilized."	1.31	Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. ( Chiarello, SE, 2000)
"Metastatic breast cancer is a common clinical entity, and its treatment is still a major clinical problem in modern oncology."	1.31	Effect of cisplatin on skin metastasis in breast cancer patients. ( Altinova, AE; Coşkun, U; Gunel, N; Yamac, D, 2001)
"Skin biopsy confirmed the diagnosis of extramammary Paget's disease, and a CT scan revealed multiple metastases to the lymph nodes along the iliac artery and aorta."	1.31	Docetaxel induced durable response in advanced extramammary Paget's disease: a case report. ( Kaneko, M; Oguchi, S; Saida, T; Uhara, H, 2002)
"Twenty-six patients with biopsy-proven Bowen's disease received eight 5-FU iontophoretic treatments in 4 weeks."	1.30	5-fluorouracil iontophoretic therapy for Bowen's disease. ( Anderson, LL; Grabski, WJ; McCollough, ML; Menon, PA; Skelton, HG; Smith, KJ; Welch, ML, 1997)
"A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy in a 54-year-old woman, is reported."	1.30	[A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy]. ( Fujino, H; Itoshima, T; Kasamatsu, T; Kodama, M; Morita, Y; Yamamoto, H; Yamamoto, T, 1997)
"Merkel cell carcinoma is a rare and highly aggressive skin tumor."	1.30	The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. ( Brenner, B; Fenig, E; Hana, MB; Katz, A; Rakovsky, E; Sulkes, A, 1997)
"5-Fluorouracil was used at 3."	1.30	Destructive procedures are the standard of care for treatment of actinic keratoses. ( Feldman, SR; Fleischer, AB; Jorizzo, JL; Williford, PM, 1999)
"These guidelines for management of Bowen's disease have been prepared for dermatologists on behalf of the British Association of Dermatologists."	1.30	Guidelines for management of Bowen's disease. British Association of Dermatologists. ( Cox, NH; Eedy, DJ; Morton, CA, 1999)
"The major limitation in the treatment of malignant melanoma is the lack of availability of effective agents for treatment."	1.29	Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. ( Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M, 1994)
"The rosacea was associated with episodes of diarrhoea."	1.29	[Carcinoid tumor with revealed by skin manifestation]. ( Cuny, JF; Grandidier, M; Reichert, S; Truchetet, F, 1994)
"A 58-year-old man with basal cell nevus syndrome had variously sized basal cell epitheliomas (BCEs), mostly of the superficial type, on his chest, back, and lumbar areas."	1.29	Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. ( Nishimura, M; Otake, N; Tsuji, T, 1993)
"Five patients with advanced Merkel cell carcinoma (MCC) are described."	1.29	The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma. ( Fenig, E; Lurie, H; Sulkes, A, 1993)
"Levamisole is an effective antihelminthic drug with immunomodulatory and anticancer activities in model systems."	1.28	Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. ( Kovach, JS; Schaid, DJ; Svingen, PA, 1992)
"A 62-year-old female with anal cancer underwent Miles operation in November, 1987."	1.28	[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989)
"A review of 20 patients with postburn scar carcinoma is presented."	1.28	Postburn scar carcinoma. ( Aron, NK; Tajuri, S, 1989)
"A histologically confirmed case of Bowen's disease in multiple nail beds in the hands of a 40-year-old is reported."	1.27	Bowen's disease in multiple nail beds--case report. ( Strong, ML, 1983)
"The true extent of the skin affected in extramammary Paget's disease is frequently well beyond its clinical borders."	1.27	Role of preoperative topical 5-fluorouracil in preparation for Mohs micrographic surgery of extramammary Paget's disease. ( Eliezri, YD; Horan, DB; Silvers, DN, 1987)
"A case of extramammary Paget's disease is reported."	1.27	Metastatic extramammary Paget's disease: dramatic response to combined modality treatment. ( Athar, M; Balducci, L; Crawford, ED; Khansur, T; McKenzie, D; Smith, GF, 1988)
"Vitiligo is characterized by depigmentation in large or small areas of the skin."	1.27	Vitiligo. ( Dunn, JF, 1986)
"In white persons, most skin cancer occurs in sites that have been exposed to sunlight for long periods."	1.26	Dysplastic epidermal keratosis in a black woman. ( Kelly, AP; Lopansri, S; Weaver, SM, 1981)
"The increased incidence of skin cancer and its possible cause is briefly discussed and the role of immunobiologic factors in the development of squamous cell carcinomas is mentioned."	1.26	Squamous cell carcinoma. Case report of an unusually aggressive skin cancer. ( Biro, L; Price, E, 1979)
"Sixty-six confirmed cases of Bowen's disease (intraepidermal squamous cell carcinoma) were seen from 1965 through 1976: twenty-four cases were treated surgically-four by excision (two recurrences) and twenty by desiccation and curettage (four recurrences); one was treated with x-ray radiation; and forty-one were treated with topical 5-fluorouracil (5-FU) (three recurrences)."	1.26	Bowen's disease and 5-fluorouracil. ( Sturm, HM, 1979)
"A case of extensive Bowen's disease of the skin treated successfully with topical 5-fluor-uracil is described."	1.26	[Therapy of morbus Bowen with 5-fluoro-uracil ointment (author's transl)]. ( Grussendorf, EI; Krause, H, 1979)
"The 12th case of Bowen's disease, presented here, offers an alternative method of treatment using 5-fluorouracil combined with a keratolytic ointment."	1.26	Bowen's disease of the nail bed: a case presentation and review of the literature. ( Defiebre, BK, 1978)
"Four cases of Bowen's disease of the finger have been treated, three during the past two years."	1.26	Bowen's Disease of the Finger. ( Kern, AB; Schiff, BL, 1977)
"An ususual case of Bowen's disease of the skin of the penile shaft treated successfully with topical 5-fluorouracil is presented along with a review of different modes of treatment."	1.26	Bowen's disease of shaft of penis. Successful treatment with 5-fluorouracil. ( Castro, VL; Mouded, IM; Newman, HR; Tolia, BM, 1976)
"In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C."	1.25	An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975)
"The relation between the induction of delayed hypersensitivity reactions to 5-FU following treatment with topical 5-FU and the cure rate for cutaneous neoplasms showed a trend toward correlation."	1.25	Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers. ( Ichinose, H; Krementz, ET; Litwin, MS; Mansell, PW, 1975)

Research

Studies (694)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Hazard Ratio for Surgically Treated KC

Timeframe	Studies, this research(%)	All Research%
pre-1990	271 (39.05)	18.7374
1990's	57 (8.21)	18.2507
2000's	105 (15.13)	29.6817
2010's	190 (27.38)	24.3611
2020's	71 (10.23)	2.80

Authors	Studies
Kuria, KA	1
Chepkwony, H	1
Govaerts, C	1
Roets, E	1
Busson, R	1
De Witte, P	1
Zupko, I	1
Hoornaert, G	1
Quirynen, L	1
Maes, L	1
Janssens, L	1
Hoogmartens, J	1
Laekeman, G	1
Neale, H	1
Michelon, M	1
Jacob, S	1
Pinkston, M	1
Ukaegbu, R	1
Zamor, W	1
Morrison, E	1
Deng, A	1
Levin, NA	1
Yuan, C	1
Long, X	1
Li, J	1
Cai, Q	1
Hamad, J	1
Jolly, PS	1
Iqubal, MK	2
Iqubal, A	2
Anjum, H	1
Gupta, MM	2
Ali, J	2
Baboota, S	2
Gonsalves, A	1
Tambe, P	1
Le, D	1
Thakore, D	1
Wadajkar, AS	1
Yang, J	1
Nguyen, KT	1
Menon, JU	1
Fredman, G	1
Wenande, E	3
Hendel, K	2
Togsverd-Bo, K	3
Haedersdal, M	5
Mohney, L	1
Singh, R	1
Grada, A	1
Feldman, S	1
Panda, S	1
Bhol, CS	1
Bhutia, SK	1
Mohapatra, S	1
Pourmanouchehri, Z	1
Ebrahimi, S	1
Limoee, M	1
Jalilian, F	1
Janfaza, S	1
Vosoughi, A	1
Behbood, L	1
Rana, K	2
Kumar Pandey, S	1
Chauhan, S	1
Preet, S	2
Ahmady, S	1
Jansen, MHE	4
Nelemans, PJ	9
Kessels, JPHM	1
Arits, AHMM	5
de Rooij, MJM	2
Essers, BAB	4
Quaedvlieg, PJF	3
Kelleners-Smeets, NWJ	6
Mosterd, K	11
Samimi, M	1
Cheng, B	1
Veerabagu, S	1
Miller, CJ	2
Sobanko, JF	1
Shin, TM	1
Higgins, HW	1
Giordano, CN	1
Etzkorn, JR	2
Nicolás-Morala, J	1
Portillo-Esnaola, M	1
Terrén, S	1
Gutiérrez-Pérez, M	1
Gilaberte, Y	2
González, S	2
Juarranz, Á	1
David, P	1
Baum, S	1
Shoenfeld, Y	1
Gil-Lianes, J	1
Morgado-Carrasco, D	1
Algarin, YA	1
Jambusaria-Pahlajani, A	3
Ruiz, E	1
Patel, VA	2
Yu, Y	1
Zhang, G	2
Fu, S	1
Worley, B	3
Harikumar, V	3
Reynolds, K	3
Dirr, MA	3
Christensen, RE	3
Anvery, N	3
Yi, MD	3
Poon, E	3
Alam, M	4
Kim, J	1
Savory, SA	1
Demehri, S	5
Gill, JG	1
Hasan, N	2
Imran, M	2
Nadeem, M	1
Jain, D	1
Haider, K	1
Moshahid Alam Rizvi, M	1
Sheikh, A	2
Kesharwani, P	2
Kumar Jain, G	1
Jalees Ahmad, F	1
Lindberg, MR	1
DiLorenzo, A	1
DeSimone, JA	1
Dika, E	1
Mussi, M	1
Lambertini, M	1
Vaccari, S	1
Baraldi, C	1
Campione, E	2
Scotti, B	1
Stancic, BH	1
Zengarini, C	1
Lee, RC	1
Liyanage, U	1
Fry, K	1
Brown, S	1
von Schuckmann, L	1
Spelman, L	2
Soyer, HP	1
Neale, RE	1
Gordon, LG	1
Whiteman, DC	1
Olsen, CM	1
Janda, M	1
Khosrotehrani, K	1
Marka, A	1
Rodgers, D	1
Zelaya Castillo, L	1
Hoyt, B	1
Chapman, M	1
Carter, J	1
Dietz, MD	1
Zelmanski, MH	1
Choueiri, MA	1
Tiwari, N	1
Jaimini, A	1
Jain, GK	1
Ahmad, FJ	1
Azin, M	1
Ameri, AH	1
Nazarian, RM	1
Cusack, JC	1
Tsiaras, WG	1
Asgari, MM	2
Krieter, M	1
Schultz, E	1
Jakubechova, J	1
Smolkova, B	1
Furdova, A	1
Demkova, L	1
Altanerova, U	1
Nicodemou, A	1
Zeleznikova, T	1
Klimova, D	1
Altaner, C	1
Luu, W	1
McRae, MY	1
Stockfleth, E	4
Heppt, MV	1
Bégeault, N	1
Delarue, A	1
Verhoeven, C	1
Claessens, Z	1
Lubeek, SFK	1
Schers, HJ	1
Nazarali, S	1
Sajic, D	1
Mohammad, O	1
Faisal, SM	1
Ahmad, N	1
Rauf, MA	1
Umar, MS	1
Mujeeb, AA	1
Pachauri, P	1
Ahmed, A	1
Kashif, M	1
Ajmal, M	1
Zubair, S	1
Zhang, L	2
Ji, Z	1
Zhang, J	2
Yang, S	1
Collins, A	1
Savas, J	1
Doerfler, L	2
Chapalain, M	1
Baroudjian, B	1
Dupont, A	1
Lhote, R	1
Lambert, J	1
Bagot, M	1
Lebbe, C	1
Basset-Seguin, N	2
De Giorgi, V	1
Scarfì, F	1
Trane, L	1
Silvestri, F	1
Maida, P	1
Gori, A	1
Covarelli, P	1
Sharma, R	1
Navarrete-Dechent, C	1
Marghoob, AA	3
Marchetti, MA	1
Beatson, M	4
Siegel, JA	3
Chren, MM	4
Weinstock, MA	9
Maredia, H	1
Simkin, D	1
Soni, A	1
Loss, MJ	1
Cullen, JK	1
Simmons, JL	1
Parsons, PG	1
Boyle, GM	1
Dianzani, C	1
Conforti, C	1
Giuffrida, R	1
Corneli, P	1
di Meo, N	1
Farinazzo, E	1
Moret, A	1
Magaton Rizzi, G	1
Zalaudek, I	1
Fisher, J	1
Moustafa, D	1
Su, KA	2
Bartenstein, DW	1
Lilly, E	1
Kroshinsky, D	1
Hawryluk, EB	1
Borgheti-Cardoso, LN	1
Viegas, JSR	1
Silvestrini, AVP	1
Caron, AL	1
Praça, FG	1
Kravicz, M	1
Bentley, MVLB	1
Fayne, R	1
Nanda, S	1
Nichols, A	1
Shen, J	2
Cornejo, CM	1
Willenbrink, TJ	1
Schmults, CD	3
Arron, ST	1
Ruiz, ES	2
Liao, L	1
Cheng, Q	1
Zhu, G	1
Pei, F	1
Ye, S	1
Pederson, H	1
Staples, CJ	1
Housewright, C	1
Krishnan, V	1
Mitragotri, S	1
Musalli, AH	1
Talukdar, PD	1
Roy, P	1
Kumar, P	1
Wong, TW	2
Leader, N	1
Shaw, FM	3
Landow, SM	1
Cao, C	1
Parikh, P	1
Moezardalan, K	1
Anantharaman, A	1
Azarm, A	1
Lai, J	1
Yaman, Ü	1
Aslan, M	1
Ozturk, S	1
Ulubayram, K	1
Eroğlu, İ	1
Sinclair, R	1
Baker, C	1
Supranowicz, M	1
MacMahon, B	1
Gilchrest, BA	1
Mogensen, M	1
Bagger, C	1
Mårtensson, NL	1
Persson, DP	1
Lerche, CM	2
Husted, S	1
Janfelt, C	1
Anderson, RR	1
Lakhani, R	1
Khullar, G	1
Sharma, S	1
Saxena, AK	1
Bhargava, A	1
Rata, DM	1
Cadinoiu, AN	1
Atanase, LI	1
Popa, M	1
Mihai, CT	1
Solcan, C	1
Ochiuz, L	1
Vochita, G	1
Maxfield, L	1
Shah, M	1
Schwartz, C	1
Tanner, LS	1
Appel, J	1
Heron, CE	1
Feldman, SR	2
Ombredane, AS	1
de Andrade, LR	1
Bonadio, RS	1
Pinheiro, WO	1
de Azevedo, RB	1
Joanitti, GA	1
Maghfour, J	1
Kuraitis, D	1
Murina, A	1
Balagholi, S	1
Aletaha, M	1
Kanavi, MR	1
Karami, S	1
Dabbaghi, R	1
Nakhaie, PA	1
Nahm, WJ	1
Zito, PM	1
Gonzalez, AM	1
Nagrani, N	1
Moore, K	1
Badiavas, EV	1
Kirsner, RS	1
Nichols, AJ	1
Kokolakis, G	1
Sabat, R	1
Krüger-Krasagakis, S	1
Eberle, J	1
Malvi, P	1
Janostiak, R	1
Nagarajan, A	1
Zhang, X	1
Wajapeyee, N	1
Imtiyaz, K	1
Rizvi, MMA	1
Bennardo, L	1
Bennardo, F	1
Giudice, A	1
Passante, M	1
Dastoli, S	1
Morrone, P	1
Provenzano, E	1
Patruno, C	1
Nisticò, SP	1
Singh, M	1
Mehta Grewal, A	1
Singh, H	1
Sharma, M	1
Kaur, M	1
Gupta, P	1
Zadeng, Z	1
Stewart, JR	1
Lang, ME	1
Brewer, JD	1
Fronek, L	1
Harrison, A	1
Cooper, H	1
Dorton, D	1
Lv, R	1
Sun, Q	1
Ariza, S	1
Espinosa, S	1
Naranjo, M	1
Pomerantz, H	1
Lew, R	1
Arits, AH	5
Hendriks, MR	1
Kelleners-Smeets, NW	6
Olesen, UH	1
Bojesen, S	1
Gehl, J	1
Damps, T	1
Laskowska, AK	1
Kowalkowski, T	1
Prokopowicz, M	1
Puszko, AK	1
Sosnowski, P	1
Czuwara, J	1
Konop, M	1
Różycki, K	1
Borkowska, JK	1
Misicka, A	1
Rudnicka, L	1
Al-Haseni, A	1
Chitgopeker, P	1
Ho, JD	1
Goldberg, LJ	1
Sahni, D	1
Roozeboom, MH	5
Sommer, A	3
van Pelt, HPA	1
Steijlen, PM	3
Haeusler, KA	1
Hall, JR	1
Seykora, CM	1
Abuzeid, MJ	1
Dalton, SR	1
Jansen, MH	1
Appelen, D	1
Winnepenninckx, VJ	2
Erlendsson, AM	1
Thwin, SS	1
Marcolivio, K	1
Means, AD	2
Leader, NF	2
Hogan, D	1
Eilers, D	1
Swetter, SM	2
Chen, SC	1
Jacob, SE	1
Warshaw, EM	1
Stricklin, GP	1
Dellavalle, RP	1
Sidhu-Malik, N	1
Konnikov, N	3
Werth, VP	1
Keri, JE	1
Robinson-Bostom, L	2
Ringer, RJ	1
Lew, RA	1
Ferguson, R	1
DiGiovanna, JJ	2
Huang, GD	1
Hwang, J	1
Soung, NK	1
Han, HJ	1
Lee, Y	1
Choi, TW	1
Mun, J	1
Cha-Molstad, H	1
Lee, KH	1
Kim, HJ	1
Lee, HG	1
Hong, JT	1
Ahn, JS	1
Kwon, YT	1
Kim, BY	1
Kato, H	1
Watanabe, S	1
Kariya, K	1
Nakamura, M	1
Morita, A	1
Kurniadi, I	1
Yamada, D	1
Wirya, AY	1
Norimatsu, Y	1
Kuzumi, A	1
Ogaki, J	1
Takahashi, N	1
Sato, S	1
Yoon, J	1
Phibbs, CS	1
Chow, A	1
Prince, GT	1
Cameron, MC	1
Fathi, R	2
Alkousakis, T	1
Petrilli, R	3
Eloy, JO	3
Paschoal, JAR	1
Lopez, RFV	2
Li, AW	1
Lalor, LE	1
Bellodi Schmidt, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Value of Optical Coherence Tomography in Discrimination Between the Presence and Absence of Invasion in Clinical Actinic Keratosis[NCT06014697]		75 participants (Anticipated)	Observational	2023-03-01	Active, not recruiting
Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study[NCT02281682]	Phase 4	624 participants (Actual)	Interventional	2014-11-30	Active, not recruiting
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912]	Phase 4	954 participants (Actual)	Interventional	2009-06-26	Completed
Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial[NCT03909646]	Phase 4	250 participants (Anticipated)	Interventional	2019-05-27	Recruiting
Calcipotriol Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients[NCT04642287]	Phase 2	64 participants (Anticipated)	Interventional	2026-01-31	Not yet recruiting
Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients[NCT04329221]	Phase 2	62 participants (Anticipated)	Interventional	2026-01-01	Not yet recruiting
Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406]	Phase 1	30 participants (Anticipated)	Interventional	2018-08-03	Recruiting
The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions[NCT02019355]	Early Phase 1	132 participants (Actual)	Interventional	2013-10-31	Completed
Combination Topical 5-fluorouracil 5% / Calcipotriene 0.005% Cream for Treatment of in Situ and Superficially Invasive Squamous Cell Carcinoma of the Skin[NCT04839731]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-04-14	Recruiting
Combination Calcipotriene 0.005% Foam and Fluorouracil 5% Cream for the Treatment of Actinic Keratoses on the Scalp[NCT03996252]	Early Phase 1	15 participants (Actual)	Interventional	2019-07-01	Terminated (stopped due to The study team was not able to start the study and they never completed the IRB submission, so the study was terminated.)
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851]	Phase 2	16 participants (Actual)	Interventional	2015-04-30	Active, not recruiting
Research on Current Prototypes of the Digiclamp. Short Term and Long Term Outcomes of Treating Adults With Achrocordons (Skin Tags)[NCT03259295]		20 participants (Actual)	Interventional	2017-12-01	Completed
Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358]	Phase 1	49 participants (Actual)	Interventional	2019-03-23	Terminated (stopped due to Study terminated because of COVID19 pandemics.)
Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902]	Phase 1/Phase 2	110 participants (Anticipated)	Interventional	1999-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years

The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed

Intervention	participants (Number)
Arm 1: 5-fluorouracil	182
Arm 2: Placebo, Vehicle Control	177

Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years

Percentage of Discoloration Among Subjects

Intervention	years (Median)
Arm 1: 5-fluorouracil	3.37
Arm 2: Placebo, Vehicle Control	3.52

Percentage of subjects who develop discoloration at the site of removal (NCT03259295)
Timeframe: 3 months

Percentage of Pain/Numbness Where Skin Tag Was Removed

Intervention	Participants (Count of Participants)
Skin Tag Removal Initial Visit Plus Follow-up	3

Percentage of subjects who develop pain/numbness at the site of removal (NCT03259295)
Timeframe: 3 months

Percentage of Permanent Scars Among Lesion Sites

Intervention	Participants (Count of Participants)
Skin Tag Removal Initial Visit Plus Follow-up	0

Percentage of subjects who develop a scar at the removal site (NCT03259295)
Timeframe: 3 months

Percentage of Scar Tissue Formation Among Lesion Sites

Intervention	Participants (Count of Participants)
Skin Tag Removal Initial Visit Plus Follow-up	1

Percentage of subjects who develop scar tissue or keloid at the site of removal (NCT03259295)
Timeframe: 3 months

Re-occurrence Rate of Skin Tags

Intervention	Participants (Count of Participants)
Skin Tag Removal Initial Visit Plus Follow-up	0

Percentage of subjects who experience a re-occurrence of the skin tag at the removal site. (NCT03259295)
Timeframe: 3 months

Article	Year
Use of Topical Calcipotriol Plus 5-Fluorouracil in the Treatment of Actinic Keratosis: A Systematic Review. Journal of drugs in dermatology : JDD, 2022, Jan-01, Volume: 21, Issue:1 Topics: Acetamides; Calcitriol; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis, Actinic; Morpholi	2022
Advances in Topical Treatments of Cutaneous Malignancies. American journal of clinical dermatology, 2023, Volume: 24, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiqui	2023
Treatment of actinic keratosis: a systematic review. Archives of dermatological research, 2023, Volume: 315, Issue:5 Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou	2023
Treatment of actinic keratosis: a systematic review. Archives of dermatological research, 2023, Volume: 315, Issue:5 Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou	2023
Treatment of actinic keratosis: a systematic review. Archives of dermatological research, 2023, Volume: 315, Issue:5 Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou	2023
Treatment of actinic keratosis: a systematic review. Archives of dermatological research, 2023, Volume: 315, Issue:5 Topics: Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Photochemotherapy; Skin Neoplasms; Treatment Ou	2023
Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer. Environmental research, 2023, 09-15, Volume: 233 Topics: Cannabidiol; Drug Carriers; Fluorouracil; Humans; Lipids; Nanostructures; Particle Size; Skin; Skin	2023
Intralesional 5-fluorouracil as a management for cutaneous squamous cell carcinomas: A rural Australian retrospective case series. The Australasian journal of dermatology, 2023, Volume: 64, Issue:4 Topics: Aged; Aged, 80 and over; Australia; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Mi	2023
Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion. Acta dermato-venereologica, 2023, Nov-20, Volume: 103 Topics: Adult; Emollients; Expert Testimony; Fluorouracil; Humans; Keratosis, Actinic; Skin; Skin Neoplasms	2023
Nonsurgical Treatments for Nonmelanoma Skin Cancer. Dermatologic clinics, 2019, Volume: 37, Issue:4 Topics: Administration, Cutaneous; Anilides; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bi	2019
Topical treatments for skin cancer. Advanced drug delivery reviews, 2020, 01-01, Volume: 153 Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; D	2020
Current therapies for actinic keratosis. International journal of dermatology, 2020, Volume: 59, Issue:6 Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac	2020
Nanotechnology approaches in the current therapy of skin cancer. Advanced drug delivery reviews, 2020, 01-01, Volume: 153 Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Drug Resistance, Neopl	2020
Field cancerization: Treatment. Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:3 Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinogenesi	2020
Nanoparticles for topical drug delivery: Potential for skin cancer treatment. Advanced drug delivery reviews, 2020, 01-01, Volume: 153 Topics: Administration, Cutaneous; Antineoplastic Agents; Dacarbazine; Drug Carriers; Fluorouracil; Gold; Hu	2020
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies. The Australasian journal of dermatology, 2021, Volume: 62, Issue:2 Topics: Antineoplastic Agents; Diclofenac; Disease Progression; Diterpenes; Fluorouracil; Humans; Imiquimod;	2021
Actinic Keratoses: Reconciling the Biology of Field Cancerization with Treatment Paradigms. The Journal of investigative dermatology, 2021, Volume: 141, Issue:4 Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Transformation, Neo	2021
Intralesional 5-Fluorouracil for Treatment of Non-Melanoma Skin Cancer: A Systematic Review. Journal of drugs in dermatology : JDD, 2021, 02-01, Volume: 20, Issue:2 Topics: Biopsy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Fluorouracil;	2021
Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far? Current oncology (Toronto, Ont.), 2021, 06-23, Volume: 28, Issue:4 Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Neoplasm Recurrence, Local; Skin Neoplasm	2021
Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:1 Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Fluorouracil; Humans; Imiquimod; Skin Neoplasms	2022
A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment. Journal of cellular biochemistry, 2017, Volume: 118, Issue:11 Topics: Aminoquinolines; Cryotherapy; Fluorouracil; Humans; Imiquimod; Melanoma; Photochemotherapy; PubMed;	2017
Nonsurgical Therapies for Basal Cell Carcinoma: A Review. Actas dermo-sifiliograficas, 2017, Volume: 108, Issue:9 Topics: Administration, Cutaneous; Aminoquinolines; Anilides; Antineoplastic Agents; Biphenyl Compounds; Car	2017
Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders. Seminars in cutaneous medicine and surgery, 2017, Volume: 36, Issue:4 Topics: Administration, Cutaneous; Anesthetics, Local; Antineoplastic Agents; Cicatrix; Cosmetic Techniques;	2017
Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. Journal of drugs in dermatology : JDD, 2018, Mar-01, Volume: 17, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Cicatrix, Hypertrophic; Fluorouracil; Humans; Injections,	2018
Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, Volume: 80, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Fluoro	2019
Annales de dermatologie et de venereologie, 2018, Volume: 145 Suppl 5 Topics: Alopecia; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basal Cel	2018
Mediators of Inflammation in Topical Therapy of Skin Cancers. Mediators of inflammation, 2019, Volume: 2019 Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineop	2019
Intralesional therapy for the treatment of keratoacanthoma. Dermatologic therapy, 2019, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Dermatologic Agents; Fluorouracil; Humans; Injectio	2019
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. Dermatologic clinics, 2019, Volume: 37, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci	2019
Treatment of Solitary Keratoacanthoma of the Nose With Intralesional Methotrexate and Review of the Literature Journal of drugs in dermatology : JDD, 2019, Jul-01, Volume: 18, Issue:7 Topics: Antineoplastic Agents; Biopsy; Bleomycin; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; In	2019
Microinvasive melanoma: cutaneous pharmacotherapeutic approaches. American journal of clinical dermatology, 2013, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Ne	2013
Pharmacogenetics in dermatology: a patient-centered update. International journal of dermatology, 2013, Volume: 52, Issue:8 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo	2013
Interventions for cutaneous Bowen's disease. The Cochrane database of systematic reviews, 2013, Jun-24, Issue:6 Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Cryotherapy; Fluoroura	2013
Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:9 Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell;	2013
Outdated dermatologic drug samples and obligations to the patient. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:4 Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Dermatology; Fluorouracil; Humans; Liabili	2013
Actinic keratosis: new concepts and therapeutic approaches for an ancestral condition. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:9 Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cryotherapy; Electrocoagulation; Fluorour	2014
Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatology, photoimmunology & photomedicine, 2015, Volume: 31, Issue:1 Topics: Administration, Topical; Aminoquinolines; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Fl	2015
Before or after: is there a connection between the use of adjunctive nonmelanoma skin cancer treatments and subsequent invasive tumors? Journal of drugs in dermatology : JDD, 2015, Volume: 14, Issue:5 Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Humans; Imiquimod; Neop	2015
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. International journal of dermatology, 2016, Volume: 55, Issue:3 Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma,	2016
Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review. Journal of the American Academy of Dermatology, 2016, Volume: 74, Issue:3 Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Skin Neoplasms	2016
Treatment of Basal Cell Carcinoma in the Elderly: What Nondermatologists Need to Know. The American journal of medicine, 2016, Volume: 129, Issue:7 Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Combined Modality Therapy;	2016
Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. Seminars in oncology, 2016, Volume: 43, Issue:3 Topics: Carcinoma, Squamous Cell; Cryosurgery; Fluorouracil; Humans; Immunosuppressive Agents; Microsurgery;	2016
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments. Actas dermo-sifiliograficas, 2016, Volume: 107, Issue:9 Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-St	2016
Actinic keratoses. Cancer treatment and research, 2009, Volume: 146 Topics: Aged; Aminoquinolines; Carcinoma, Squamous Cell; Cryotherapy; Dermatology; Fluorouracil; Humans; Imi	2009
Topical treatment of field cancerization. Cancer treatment and research, 2009, Volume: 146 Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci	2009
Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer. Molecular diagnosis & therapy, 2009, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Fluorouracil; Humans; Pharmacogenetics; S	2009
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. The Journal of dermatological treatment, 2009, Volume: 20, Issue:6 Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic	2009
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Archives of dermatology, 2009, Volume: 145, Issue:12 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, S	2009
Intralesional agents in the management of cutaneous malignancy: a review. Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:2 Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci	2011
Treating skin cancer with topical cream. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:9 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac;	2010
Actinic keratoses: past, present and future. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:5 Suppl OD Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou	2010
Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. Journal of the American Academy of Dermatology, 2010, Volume: 63, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamou	2010
Actinic cheilitis: a treatment review. International journal of dermatology, 2010, Volume: 49, Issue:11 Topics: Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Caustics; Cheilitis; Cryosurgery;	2010
Solitary subcutaneous metastasis from squamous cell carcinoma of the esophagus: a case report and brief review of literature. Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop	2011
Topical antineoplastic agents in the treatment of mucocutaneous diseases. Current problems in dermatology, 2011, Volume: 40 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; I	2011
Do lasers or topicals really work for nonmelanoma skin cancers? Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:1 Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents;	2011
Squamous cell carcinomas of the lower limbs in African American women. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Biopsy, Needle; Black or African American; Carcino	2011
Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2 Topics: Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dermatologic Agent	2011
Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2012, Volume: 38, Issue:1 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diclofenac; Fluorouracil; Humans; I	2012
Emerging treatments and signaling pathway inhibitors. Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:4 Suppl Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Basal Cell Nevus Syndrome; Benzamides; Carcinoma,	2011
Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens. Current opinion in ophthalmology, 2012, Volume: 23, Issue:5 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, S	2012
Diagnosis and treatment of Basal cell and squamous cell carcinoma. American family physician, 2012, Jul-15, Volume: 86, Issue:2 Topics: Aminoquinolines; Antineoplastic Agents; Biopsy; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cry	2012
The use of topical fluorouracil to treat actinic keratosis. Cutis, 2002, Volume: 70, Issue:2 Suppl Topics: Administration, Topical; Antimetabolites, Antineoplastic; Dermatologic Agents; Fluorouracil; Humans;	2002
Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod. Cutis, 2003, Volume: 71, Issue:5 Topics: Administration, Cutaneous; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents;	2003
Treatment of nonmelanoma skin cancer in organ transplant recipients: review of responses to a survey. Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:3 Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Cryosurgery; Electrosurg	2003
Current treatment patterns in non-melanoma skin cancer across Europe. The Journal of dermatological treatment, 2003, Volume: 14 Suppl 3 Topics: Administration, Cutaneous; Aminoquinolines; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryothe	2003
[Cutaneous neoplasms]. Praxis, 2003, Sep-03, Volume: 92, Issue:36 Topics: Adjuvants, Immunologic; Aminoquinolines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bio	2003
Topical and light-based treatments for actinic keratoses. Seminars in cutaneous medicine and surgery, 2003, Volume: 22, Issue:3 Topics: Adjuvants, Immunologic; Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Antineoplasti	2003
Management of Bowen's disease of the skin. Drug and therapeutics bulletin, 2004, Volume: 42, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Bowen's Disease; Costs and Cost Analysis; Cryotherapy; Fluoro	2004
Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Seminars in cutaneous medicine and surgery, 2004, Volume: 23, Issue:3 Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag	2004
Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). American journal of clinical dermatology, 2004, Volume: 5, Issue:6 Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic;	2004
Photodynamic therapy. The Australasian journal of dermatology, 2005, Volume: 46 Suppl 3 Topics: Administration, Topical; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Cryotherapy; Fluorour	2005
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. The Journal of family practice, 2006, Volume: 55, Issue:5 Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Consens	2006
[Actinic keratosis]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Adjuvants, Immunologic; Age Factors; Aged; Aminoquinolines; Antimetabolites, Antineoplastic; Antineo	2006
Guidelines for management of Bowen's disease: 2006 update. The British journal of dermatology, 2007, Volume: 156, Issue:1 Topics: Adjuvants, Immunologic; Aminoquinolines; Bowen's Disease; Cautery; Cryotherapy; Curettage; Disease P	2007
Therapeutic options for Bowen's disease. The Australasian journal of dermatology, 2007, Volume: 48, Issue:1 Topics: Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Cautery; Cryotherapy; Fluorouracil; Humans;	2007
Actinic keratoses. Australian family physician, 2007, Volume: 36, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Australia; Cryotherapy; Diclofenac; Fluoro	2007
Treatment options for actinic keratoses. American family physician, 2007, Sep-01, Volume: 76, Issue:5 Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag	2007
Nevoid basal cell carcinoma syndrome (Gorlin syndrome): updated review of minimally invasive treatments. Cutis, 2008, Volume: 81, Issue:1 Topics: Aminoquinolines; Antineoplastic Agents; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cryosurger	2008
Topical therapy for actinic keratoses: current and evolving therapies. Reviews on recent clinical trials, 2006, Volume: 1, Issue:1 Topics: Administration, Cutaneous; Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinom	2006
Dermatological aspects of aging. The Medical clinics of North America, 1983, Volume: 67, Issue:2 Topics: Adult; Aged; Aging; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Female; Fl	1983
Treatment of skin cancer using multiple modalities. Journal of the American Academy of Dermatology, 1982, Volume: 7, Issue:2 Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F	1982
Topical chemotherapy with 5-fluorouracil. A review. Journal of the American Academy of Dermatology, 1981, Volume: 4, Issue:6 Topics: Administration, Topical; Chemical Phenomena; Chemistry; Dermatitis, Atopic; Dermatitis, Contact; Fem	1981
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. Cancer treatment and research, 1993, Volume: 65 Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas	1993
[Bowen's disease. A report of 9 cases]. Atencion primaria, 1994, Mar-15, Volume: 13, Issue:4 Topics: Aged; Bowen's Disease; Diagnosis, Differential; Female; Fluorouracil; Humans; Male; Middle Aged; Neo	1994
Therapeutic perspectives in actinic and other keratoses. International journal of dermatology, 1996, Volume: 35, Issue:8 Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Cryosurgery; Fluorouracil; Humans; Kerat	1996
[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Sch	1997
Actinic cheilitis. A treatment review. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 1997, Volume: 23, Issue:1 Topics: Cheilitis; Cryosurgery; Electrocoagulation; Fluorouracil; Humans; Laser Therapy; Precancerous Condit	1997
Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Cutis, 1999, Volume: 64, Issue:1 Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Cryotherapy; Dicarboxylic Acids; Female; Flu	1999
Advances in the treatment of basal cell carcinoma: the promise of pharmacologic therapy. Advances in dermatology, 2000, Volume: 16 Topics: Adjuvants, Immunologic; Carcinoma, Basal Cell; Fluorouracil; Humans; Interferons; Photochemotherapy;	2000
[Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients]. Medicina clinica, 2002, Jun-01, Volume: 118, Issue:20 Topics: Acquired Immunodeficiency Syndrome; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agen	2002
Nonmelanoma skin cancer. Current treatment options in oncology, 2002, Volume: 3, Issue:3 Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diet Therapy; Fluorouracil; Humans; Life Style; Neo	2002
Current dermatologic therapy. Cutis, 1976, Volume: 18, Issue:4 Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antifungal A	1976
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals of internal medicine, 1979, Volume: 91, Issue:2 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud	1979
Alternative management of cutaneous squamous cell carcinoma in an elderly man: report of a case and review of the literature. Journal of the American Geriatrics Society, 1992, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External;	1992
Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. Cancer, 1990, Sep-15, Volume: 66, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterization, Ce	1990
Emulsion and activated carbon in cancer chemotherapy. Critical reviews in therapeutic drug carrier systems, 1986, Volume: 2, Issue:3 Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as	1986
[Complete remission (clinical and histologic) of an advanced squamous cell epithelioma treated only by chemotherapy]. Annales de dermatologie et de venereologie, 1988, Volume: 115, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin	1988
[A case of bowenoid papulosis of the penis]. Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:3 Topics: Adult; Bowen's Disease; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male; Ointments; Penis; Skin	1989
A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil. Obstetrical & gynecological survey, 1985, Volume: 40, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anal Canal; Anus Neoplasms; Carc	1985
A role for topical 5-fluorouracil therapy in melanoma. Journal of surgical oncology, 1988, Volume: 38, Issue:4 Topics: Administration, Topical; Adult; Aged; Child; Female; Fluorouracil; Humans; Male; Melanoma; Skin Neop	1988
The use of cytotoxic drugs in the surgery of malignant disease. The Journal of bone and joint surgery. British volume, 1968, Volume: 50, Issue:3 Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma,	1968
[Use of optical quantum generators (lasers) in oncology]. Voprosy onkologii, 1972, Volume: 18, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom	1972
Local cytostatic chemotherapy and immunotherapy. Geriatrics, 1968, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Drug Hypersensitivity; Fluorouracil; Humans; Neoplasms	1968
Current progress in the management of cancer. A collective review. Plastic and reconstructive surgery, 1969, Volume: 44, Issue:3 Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem	1969
Topical treatment of skin tumours with 5-fluorouracil. The British journal of dermatology, 1970, Volume: 82, Issue:2 Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratosis; Skin Neoplasms	1970
Topical antimetabolites. Annual review of medicine, 1970, Volume: 21 Topics: Antimetabolites; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Folic Acid Antagonists;	1970
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture. Cancer research, 1970, Volume: 30, Issue:6 Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi	1970
The metabolism and pharmacology of 5-fluorouracil. Journal of surgical oncology, 1971, Volume: 3, Issue:3 Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber	1971

Article	Year
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA dermatology, 2022, 06-01, Volume: 158, Issue:6 Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S	2022
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA dermatology, 2022, 06-01, Volume: 158, Issue:6 Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S	2022
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA dermatology, 2022, 06-01, Volume: 158, Issue:6 Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S	2022
Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA dermatology, 2022, 06-01, Volume: 158, Issue:6 Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Male; S	2022
Effects of increased actinic keratosis count on skin-related quality of life: results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial. European journal of dermatology : EJD, 2019, Oct-01, Volume: 29, Issue:5 Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Count; Chemoprevention; Dermatologic Agents; Double	2019
Validation and comparison of quality-of-life measures for topical 5-fluorouracil treatment: results from a randomized controlled trial. Clinical and experimental dermatology, 2017, Volume: 42, Issue:5 Topics: Administration, Cutaneous; Analysis of Variance; Female; Fluorouracil; Humans; Male; Quality of Life	2017
Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma: a discrete choice experiment. The British journal of dermatology, 2018, Volume: 178, Issue:1 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Choice Behavior; Dermatologic Agents; Drug Therapy, Comb	2018
Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA dermatology, 2018, 02-01, Volume: 154, Issue:2 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamou	2018
Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis. Journal of the American Academy of Dermatology, 2018, Volume: 79, Issue:3 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Basa	2018
Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. Journal of the American Academy of Dermatology, 2018, Volume: 79, Issue:5 Topics: Adult; Aged; Carcinoma, Basal Cell; Dermatologic Surgical Procedures; Esthetics; Female; Fluorouraci	2018
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI insight, 2019, 03-21, Volume: 4, Issue:6 Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri	2019
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI insight, 2019, 03-21, Volume: 4, Issue:6 Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri	2019
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI insight, 2019, 03-21, Volume: 4, Issue:6 Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri	2019
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI insight, 2019, 03-21, Volume: 4, Issue:6 Topics: Adaptive Immunity; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitri	2019
Characteristics of Keratinocyte Carcinomas and Patients with Keratinocyte Carcinomas Following a Single 2-4 Week Course of Topical 5-fluorouracil on the Face and Ears. Acta dermato-venereologica, 2019, Jun-01, Volume: 99, Issue:7 Topics: Administration, Topical; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; D	2019
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. The Lancet. Oncology, 2013, Volume: 14, Issue:7 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antim	2013
Fluorouracil and other predictors of morpheaform basal cell carcinoma among high-risk patients: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. JAMA dermatology, 2014, Volume: 150, Issue:3 Topics: Administration, Topical; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic	2014
Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. The British journal of dermatology, 2014, Volume: 171, Issue:6 Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Combined Chemotherap	2014
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast cancer research and treatment, 2014, Volume: 147, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast N	2014
Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. The Journal of investigative dermatology, 2016, Volume: 136, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Biopsy; Carcinoma, Basal Cel	2016
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. The Journal of clinical investigation, 2017, 01-03, Volume: 127, Issue:1 Topics: Administration, Topical; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Prot	2017
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es	2011
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineopla	2012
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. American journal of clinical oncology, 2011, Volume: 34, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fl	2011
Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. The British journal of dermatology, 2003, Volume: 148, Issue:3 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antimetabolites, Antineoplast	2003
Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Diseases of the colon and rectum, 2005, Volume: 48, Issue:3 Topics: Administration, Topical; Adult; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Bowen	2005
Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Archives of dermatology, 2006, Volume: 142, Issue:6 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antimetabolites, Ant	2006
Facial resurfacing for nonmelanoma skin cancer prophylaxis. Archives of dermatology, 2006, Volume: 142, Issue:8 Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Disease-Fr	2006
Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. The British journal of dermatology, 2007, Volume: 156, Issue:2 Topics: Administration, Topical; Aged; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Bowen's Disease	2007
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. The British journal of dermatology, 2007, Volume: 157 Suppl 2 Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Cryosurge	2007
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology, 2007, Volume: 73, Issue:3-4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop	2007
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi	1983
Selective cytotoxic effect of topical 5-fluorouracil. Archives of dermatology, 1983, Volume: 119, Issue:9 Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind	1983
Podophyllotoxin for condylomata acuminata eradication. Clinical and experimental comparative studies on Podophyllum lignans, colchicine and 5-fluorouracil. Acta dermato-venereologica. Supplementum, 1981, Volume: 98 Topics: Administration, Topical; Animals; Clinical Trials as Topic; Colchicine; Condylomata Acuminata; Ethan	1981
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer investigation, 1995, Volume: 13, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura	1995
Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Archives of dermatology, 1995, Volume: 131, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Fluorour	1995
Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Journal of the American Academy of Dermatology, 1997, Volume: 36, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Basal Cell; Clin	1997
A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2000, Volume: 26, Issue:4 Topics: Administration, Topical; Carcinoma, Basal Cell; Double-Blind Method; Drug Carriers; Fluorouracil; Hu	2000
Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. American journal of clinical oncology, 2000, Volume: 23, Issue:2 Topics: Administration, Oral; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell;	2000
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2001, Volume: 10, Issue:57 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide	2001
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer, 1977, Volume: 40, Issue:2 Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic;	1977
The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. Journal of the American Academy of Dermatology, 1992, Volume: 27, Issue:5 Pt 1 Topics: Adult; Aged; Carcinoma, Basal Cell; Double-Blind Method; Drug Carriers; Drug Implants; Female; Fluor	1992
Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. European journal of gynaecological oncology, 1992, Volume: 13, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Doxor	1992
Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. Journal of surgical oncology, 1992, Volume: 50, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide	1992
Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer, 1991, Apr-15, Volume: 67, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Syne	1991
Emulsion and activated carbon in cancer chemotherapy. Critical reviews in therapeutic drug carrier systems, 1986, Volume: 2, Issue:3 Topics: Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carbon; Clinical Trials as	1986
[Adjuvant 5-fluorouracil lacquer administration for reducing the rate of recurrence of condylomata acuminata following laser surgery treatment]. Der Urologe. Ausg. A, 1989, Volume: 28, Issue:3 Topics: Adult; Combined Modality Therapy; Condylomata Acuminata; Fluorouracil; Genital Neoplasms, Male; Huma	1989
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer, 1985, Jul-15, Volume: 56, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide;	1985
[Radiotherapy of malignant neoplasms following synchronisation of cell division rhythm. Experiences following two years of clinical use]. Strahlentherapie, 1972, Volume: 143, Issue:3 Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; Fluorouracil; Humans; Infusi	1972
A clinical trial of the use of 5-fluouracil in the treatment of some cutaneous malignancies. British journal of plastic surgery, 1973, Volume: 26, Issue:2 Topics: Adult; Aged; Carcinoma, Basal Cell; Clinical Trials as Topic; Facial Neoplasms; Female; Fluorouracil	1973
The use of topical 5-fluorouracil in the treatment of skin tumours--preliminary report. Journal of the Irish Medical Association, 1969, Volume: 62, Issue:380 Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Clinical Trials as Topic; Female; Fluorouracil; Humans; Kera	1969
The effects of 5-fluorouracil (5-FU) ointment in the treatment of neoplastic dermatoses. Dermatologica, 1970, Volume: 140 Topics: Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Ointments; Precancerous Conditi	1970
Treatment of basal cell carcinoma with 5-fluorouracil (5-FU) ointment. Dermatologica, 1970, Volume: 140 Topics: Aged; Carcinoma, Basal Cell; Clinical Trials as Topic; Female; Fluorouracil; Humans; Male; Middle Ag	1970
Treatment of skin epitheliomas with 5-fluorouracil (5-FU) ointment. Influence of therapeutic design on recurrence of lesions. Dermatologica, 1970, Volume: 140 Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Clinical Trials as T	1970
[Therapeutic trial with 5-fluorouracil ointment]. Hospital (Rio de Janeiro, Brazil), 1970, Volume: 77, Issue:4 Topics: Adult; Aged; Carcinoma, Basal Cell; Clinical Trials as Topic; Evaluation Studies as Topic; Facial Ne	1970
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Annals of surgery, 1968, Volume: 168, Issue:3 Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci	1968
Tumors of the skin. V. Local administration of anti-tumor agents to multiple superficial basal cell carcinomas. The Journal of investigative dermatology, 1965, Volume: 45, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Clinical Trials as Topic; Fluorouracil; Humans; Neopla	1965

fluorouracil and Cancer of Skin